Singapore Eye Research Institute Excels in Global Rankings
The Singapore Eye Research Institute (SERI) has achieved a remarkable feat by placing first among non-academic institutions in the field of ophthalmology. Furthermore, it secured an impressive second place overall among all institutes globally, as recognized by the American platform ScholarGPS. This achievement highlights SERI's commitment to its research and the significant strides made over the past five years.
Significant Achievement in Ophthalmic Research
SERI's milestone is a testament to its ongoing dedication to eye health and cutting-edge research. Over nearly three decades, the institute has established itself as a leader in ophthalmic research and biopharmaceuticals. As the research arm of the Singapore National Eye Centre, its growing influence emphasizes Singapore's status as a medical research and innovation hub in the Asia-Pacific region.
Assessing Research Performance on ScholarGPS
ScholarGPS evaluates research institutions based on key performance indicators including research output and citation impact. SERI's outstanding performance in these areas affirms its role in enhancing eye care through pioneering research and clinical excellence. Various studies on conditions like diabetic retinopathy and glaucoma have underpinned this notable recognition.
Groundbreaking Contributions to Eye Care
Among the impactful research conducted at SERI are studies addressing diabetic eye diseases, dry eye conditions, and the treatment of myopia. Moreover, the institute is venturing into innovative areas such as artificial intelligence in healthcare and digital health, which showcases its adaptability to modern technological advancements.
Community-Centric Approach to Innovation
Professor Jodhbir Mehta, Executive Director at SERI, expressed pride in the acknowledgment, stating, "The commitment of our research teams and support staff is truly commendable. This ranking affirms our mission to optimize patient care through innovative research. We are excited about the future as we continue to push limits in ophthalmology research in the upcoming year.”
The Impact of Translational Research
SERI's contributions to translational research are reshaping patient care. Innovations include Vabysmo (faricimab), which significantly reduces the frequency of eye injections for conditions such as diabetic retinopathy. Patients can now maintain their vision with fewer treatments, enhancing quality of life.
Advancing Ophthalmic Devices
The institute has also pioneered several groundbreaking medical devices such as the EndoGlide, a device approved by the US FDA for advanced corneal transplants. Additionally, SERI has developed the Polarisation-Sensitive Optical Coherence Tomography, allowing for non-invasive assessment of eye tissues and the tracking of myopia progression.
Integrating AI in Eye Care
Going beyond traditional research methods, SERI has been a pioneer in integrating artificial intelligence into ophthalmology. The development of the Singapore Eye Lesion Analyser (SELENA+) marks a significant advancement in early detection of diabetes-related eye diseases, providing essential screening tools across healthcare settings.
SERI's Expanding Global Influence
With a staggering output of scientific publications and numerous competitive grants, SERI continues to lead in ophthalmic research. Established as the largest eye research institute in the Asia-Pacific region, it collaborates with reputable clinical centers and research institutions worldwide, solidifying its global standing.
About Singapore Eye Research Institute
Founded in 1997, the Singapore Eye Research Institute (SERI) is dedicated to high-impact research aimed at combating blindness and major eye diseases prevalent among Singaporeans and Asians. Its innovations have led to significant improvements in treatment methodologies worldwide.
About Singapore National Eye Centre
Incorporated in 1989, the Singapore National Eye Centre (SNEC) is integral to Singapore’s public healthcare. With its focus on specialized ophthalmological care, it manages extensive patient cases annually, emphasizing quality education and research in eye health.
Frequently Asked Questions
What is SERI's primary achievement recognized by ScholarGPS?
SERI has achieved first place among non-academic institutions in ophthalmology and second overall globally.
What factors contributed to SERI's high ranking?
SERI's ranking is based on research output, citation impact, and overall scholarly influence in the field.
Can you name any innovative treatments developed by SERI?
SERI has developed treatments like Vabysmo and Myopine, which enhance patient care for eye diseases.
How does SERI integrate technology into eye care?
SERI employs AI tools such as the Singapore Eye Lesion Analyser (SELENA+) for early detection of eye diseases.
What is SERI's mission as a research institute?
SERI aims to conduct impactful eye research to prevent blindness and improve vision health among communities.
